Verastem Ownership
| VSTM Stock | USD 3.57 0.61 20.61% |
Shares in Circulation | First Issued 2012-03-31 | Previous Quarter 27 M | Current Value 27 M | Avarage Shares Outstanding 8.3 M | Quarterly Volatility 7.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Verastem |
Verastem Stock Ownership Analysis
About 40.0% of the company outstanding shares are owned by institutional investors. The company recorded a loss per share of 3.21. Verastem had not issued any dividends in recent years. The entity had 1:12 split on the 1st of June 2023. Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts. Verastem operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 48 people. For more information please call Daniel Paterson at 781 292 4200 or visit https://www.verastem.com.Besides selling stocks to institutional investors, Verastem also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Verastem's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Verastem's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Verastem Quarterly Liabilities And Stockholders Equity |
|
Verastem Insider Trades History
Less than 1% of Verastem are currently held by insiders. Unlike Verastem's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Verastem's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Verastem's insider trades
Verastem Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Verastem is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Verastem backward and forwards among themselves. Verastem's institutional investor refers to the entity that pools money to purchase Verastem's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-06-30 | 359 K | Kennedy Capital Management Inc | 2024-06-30 | 212.2 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 166.2 K | Sio Capital Management, Llc | 2024-06-30 | 133.4 K | Ubs O'connor Llc | 2024-06-30 | 100.4 K | Susquehanna International Group, Llp | 2024-06-30 | 89.9 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 74.8 K | Charles Schwab Investment Management Inc | 2024-06-30 | 70.8 K | Bank Of New York Mellon Corp | 2024-06-30 | 68.2 K | Bvf Inc | 2024-06-30 | 1.7 M | Soleus Capital Management, L.p. | 2024-06-30 | 1.7 M |
Verastem Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Verastem insiders, such as employees or executives, is commonly permitted as long as it does not rely on Verastem's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Verastem insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Verastem Outstanding Bonds
Verastem issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Verastem uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Verastem bonds can be classified according to their maturity, which is the date when Verastem has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Verastem Corporate Filings
8K | 17th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 9th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 8th of August 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
13A | 29th of July 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Verastem. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Verastem Stock, please use our How to Invest in Verastem guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verastem. If investors know Verastem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verastem listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.21) | Revenue Per Share 0.372 | Quarterly Revenue Growth (1.00) | Return On Assets (0.42) | Return On Equity (1.10) |
The market value of Verastem is measured differently than its book value, which is the value of Verastem that is recorded on the company's balance sheet. Investors also form their own opinion of Verastem's value that differs from its market value or its book value, called intrinsic value, which is Verastem's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verastem's market value can be influenced by many factors that don't directly affect Verastem's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verastem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verastem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verastem's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.